406 related articles for article (PubMed ID: 38374496)
1. Molecular panorama of therapy resistance in prostate cancer: a pre-clinical and bioinformatics analysis for clinical translation.
Ashrafizadeh M; Zhang W; Tian Y; Sethi G; Zhang X; Qiu A
Cancer Metastasis Rev; 2024 Mar; 43(1):229-260. PubMed ID: 38374496
[TBL] [Abstract][Full Text] [Related]
2. HZ08 suppresses RelB-activated MnSOD expression and enhances Radiosensitivity of prostate Cancer cells.
Zhang Y; Xu Z; Ding J; Tan C; Hu W; Li Y; Huang W; Xu Y
J Exp Clin Cancer Res; 2018 Jul; 37(1):174. PubMed ID: 30053873
[TBL] [Abstract][Full Text] [Related]
3. GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy.
Mukha A; Kahya U; Linge A; Chen O; Löck S; Lukiyanchuk V; Richter S; Alves TC; Peitzsch M; Telychko V; Skvortsov S; Negro G; Aschenbrenner B; Skvortsova II; Mirtschink P; Lohaus F; Hölscher T; Neubauer H; Rivandi M; Labitzky V; Lange T; Franken A; Behrens B; Stoecklein NH; Toma M; Sommer U; Zschaeck S; Rehm M; Eisenhofer G; Schwager C; Abdollahi A; Groeben C; Kunz-Schughart LA; Baretton GB; Baumann M; Krause M; Peitzsch C; Dubrovska A
Theranostics; 2021; 11(16):7844-7868. PubMed ID: 34335968
[TBL] [Abstract][Full Text] [Related]
4. WD repeat domain 5 promotes chemoresistance and Programmed Death-Ligand 1 expression in prostate cancer.
Zhou Q; Chen X; He H; Peng S; Zhang Y; Zhang J; Cheng L; Liu S; Huang M; Xie R; Lin T; Huang J
Theranostics; 2021; 11(10):4809-4824. PubMed ID: 33754029
[No Abstract] [Full Text] [Related]
5. Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Festuccia C; Muzi P; Millimaggi D; Biordi L; Gravina GL; Speca S; Angelucci A; Dolo V; Vicentini C; Bologna M
Endocr Relat Cancer; 2005 Dec; 12(4):983-98. PubMed ID: 16322337
[TBL] [Abstract][Full Text] [Related]
6. RelB upregulates PD-L1 and exacerbates prostate cancer immune evasion.
Zhang Y; Zhu S; Du Y; Xu F; Sun W; Xu Z; Wang X; Qian P; Zhang Q; Feng J; Xu Y
J Exp Clin Cancer Res; 2022 Feb; 41(1):66. PubMed ID: 35177112
[TBL] [Abstract][Full Text] [Related]
7. CMTM5 inhibits the development of prostate cancer via the EGFR/PI3K/AKT signaling pathway.
Li L; Hu Y; Chen D; Zhu J; Bao W; Xu X; Chen H; Chen W; Feng R
Mol Med Rep; 2022 Jan; 25(1):. PubMed ID: 34791506
[TBL] [Abstract][Full Text] [Related]
8. Analyzing roles of small nucleolar RNA host gene 25 from clinical, molecular target and tumor formation in prostate cancer.
Liu Z; Ke S; Wang Q; Gu X; Zhai G; Shao H; He M; Guo J
Exp Cell Res; 2023 Aug; 429(2):113686. PubMed ID: 37307941
[TBL] [Abstract][Full Text] [Related]
9. DAB2IP regulates autophagy in prostate cancer in response to combined treatment of radiation and a DNA-PKcs inhibitor.
Yu L; Tumati V; Tseng SF; Hsu FM; Kim DN; Hong D; Hsieh JT; Jacobs C; Kapur P; Saha D
Neoplasia; 2012 Dec; 14(12):1203-12. PubMed ID: 23308052
[TBL] [Abstract][Full Text] [Related]
10. STAT3 as a target for sensitizing prostate cancer cells to irradiation.
Zhang Q; Zhou XM; Wei SZ; Cui DS; Deng KL; Liang G; Luo Y; Luo B; Liang XJ
J Radiat Res; 2022 Mar; 63(2):174-182. PubMed ID: 34970978
[TBL] [Abstract][Full Text] [Related]
11. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
[TBL] [Abstract][Full Text] [Related]
12. Role of ZEB Family Members in Proliferation, Metastasis, and Chemoresistance of Prostate Cancer Cells: Revealing Signaling Networks.
Soleymani L; Zarrabi A; Hashemi F; Hashemi F; Zabolian A; Banihashemi SM; Moghadam SS; Hushmandi K; Samarghandian S; Ashrafizadeh M; Khan H
Curr Cancer Drug Targets; 2021; 21(9):749-767. PubMed ID: 34077345
[TBL] [Abstract][Full Text] [Related]
13. Prostate epithelial genes define therapy-relevant prostate cancer molecular subtype.
Han H; Lee HH; Choi K; Moon YJ; Heo JE; Ham WS; Jang WS; Rha KH; Cho NH; Giancotti FG; Choi YD
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1080-1092. PubMed ID: 33903734
[TBL] [Abstract][Full Text] [Related]
14. Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer.
Pungsrinont T; Kallenbach J; Baniahmad A
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681745
[TBL] [Abstract][Full Text] [Related]
15. PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways.
Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
Cell Death Dis; 2014 Oct; 5(10):e1437. PubMed ID: 25275598
[TBL] [Abstract][Full Text] [Related]
16. The Upregulation of PI3K/Akt and MAP Kinase Pathways is Associated with Resistance of Microtubule-Targeting Drugs in Prostate Cancer.
Liu Z; Zhu G; Getzenberg RH; Veltri RW
J Cell Biochem; 2015 Jul; 116(7):1341-9. PubMed ID: 25640606
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of miR-133a-3p promotes prostate cancer bone metastasis via activating PI3K/AKT signaling.
Tang Y; Pan J; Huang S; Peng X; Zou X; Luo Y; Ren D; Zhang X; Li R; He P; Wa Q
J Exp Clin Cancer Res; 2018 Jul; 37(1):160. PubMed ID: 30021600
[TBL] [Abstract][Full Text] [Related]
18. LncRNA RHPN1-AS1 inhibition induces autophagy and apoptosis in prostate cancer cells via the miR-7-5p/EGFR/PI3K/AKT/mTOR signaling pathway.
Ma X; Ren H; Zhang Y; Wang B; Ma H
Environ Toxicol; 2022 Dec; 37(12):3013-3027. PubMed ID: 36125241
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of miR-99b-5p and Upregulation of Nuclear mTOR Cooperatively Promotes the Tumor Aggressiveness and Drug Resistance in African American Prostate Cancer.
Gujrati H; Ha S; Waseem M; Wang BD
Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36077039
[TBL] [Abstract][Full Text] [Related]
20. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
